
    
      In this study, eligible subject will be randomized into study arm or control arm to accept
      study treatment. Subjects who randomized into control will have the opportunity to receive
      cross over treatment of SHR-1210 monotherapy after confirmed disease progression. Treatment
      cycles of chemotherapy will be 4-6 which will be decided by investigators.
    
  